Antitrust Antitrust

Pfizer, Flynn Pharma see UK dominance-abuse fines reimposed for ‘excessive’ drug pricing

By Simon Zekaria
  • 21 Jul 2022 13:54
  • 21 Jul 2022 14:33
Pfizer and Flynn Pharma today were fined a combined 70 million pounds ($83 million) by the UK competition regulator for abusing a dominant position over epilepsy-drug pricing, four years after the watchdog's previous landmark antitrust sanction against the companies was quashed in court.

The bulk of the Competition and Markets Authority fine was

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News